Get started
Author

Jaclyn Davis

ORCID: 0009-0006-1879-0057
Observed ORCID: 0009-0006-1879-0057
OpenAlex ID: A5007954572
A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
2023 · Michael J. Dickinson, Pere Barba, et al. · Cancer Discovery · 137
PDF
A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge TM platform, for the Treatment of Patients (Pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)
2021 · Ian W. Flinn, Ulrich Jaeger, et al. · Blood · 35
A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy
2020 · David G. Maloney, Michinori Ogura, et al. · Blood Advances · 33
YTB323 (Rapcabtagene Autoleucel) Demonstrates Durable Efficacy and a Manageable Safety Profile in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Phase I Study Update
2022 · Pere Barba, Mi Kwon, et al. · Blood · 15
Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study
2019 · Marinus van Oers, Lukas Smolej, et al. · Blood Cancer Journal · 13
PDF
A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab‐refractory iNHL (COMPLEMENT A + B study)
2021 · Mathias J. Rummel, Ann Janssens, et al. · British Journal of Haematology · 11
PDF
Bianca: Phase II, single-arm, global trial to determine efficacy and safety of tisagenlecleucel in pediatric/young adult (YA) patients (Pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).
2020 · Veronique Minard, Shannon L. Maude, et al. · Journal of Clinical Oncology · 6
Trial in progress: QUINTESSENTIAL—a phase 2 study of arlocabtagene autoleucel (arlo-cel) in patients with relapsed/refractory multiple myeloma (RRMM)
2025 · Ciara Louise Freeman, Sarah Larson, et al. · Blood · 2
Trial in progress: A phase 1 study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel (arlo-cel), a GPRC5D-targeted chimeric antigen receptor (CAR) T cell therapy, in combination with mezigdomide (MEZI) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
2025 · Susan Bal, Luciano Costa, et al. · Blood · 2
PDF
KarMMa-3 Subgroup Analysis in Older Patients with Relapsed/Refractory Multiple Myeloma Treated with Idecabtagene Vicleucel
2026 · Sikander Ailawadhi, Bertrand Arnulf, et al. · Transplantation and Cellular Therapy · 1
KarMMa-3 subgroup analysis in older patients with relapsed/refractory multiple myeloma treated with idecabtagene vicleucel
2025 · Sikander Ailawadhi, Bertrand Arnulf, et al. · Blood · 1
PDF
QUINTESSENTIAL: A multicenter phase 2 study evaluating the efficacy and safety of arlocabtagene autoleucel (arlo-cel) in triple- and quad-class exposed patients with relapsed or refractory multiple myeloma (RRMM).
2025 · Krina K. Patel, Sarah Marie Larson, et al. · Journal of Clinical Oncology · 1
Supplementary Data Tables from A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
2023 · Michael J. Dickinson, Pere Barba, et al. · 1
CT-526 Updated Results From a Rapcabtagene Autoleucel (YTB323) Phase I Study Demonstrate Durable Efficacy and a Manageable Safety Profile in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
2023 · Nirav N. Shah, Ian Flinn, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
PDF
Role of ofatumumab (OFA) maintenance treatment in relapsed chronic lymphocytic leukemia (CLL): Final analysis of PROLONG study.
2018 · Marinus Van Oers, Lukas Smolej, et al. · Journal of Clinical Oncology · 1
Abstract A75: Synergy between conventional chemotherapy and Cdc7 inhibition as a novel approach for cancer therapy.
2011 · Jaclyn Davis, Ronghua Zhang, et al. · Molecular Cancer Therapeutics · 1
PA-510 Trial in Progress: Phase 1 Trial of Arlocabtagene Autoleucel (Arlo-cel) Plus Mezigdomide (MEZI) or Elranatamab (ELRA) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
2026 · Susan Bal, Luciano J. Costa, et al. · Clinical Lymphoma Myeloma & Leukemia
PA-100 Clinical Trial Evidence Informing Efficacy and Safety of FDA-Approved Treatments in Relapsed and Refractory Multiple Myeloma (RRMM) for Patients (Pts) After Quadruple-Class Exposure (QCEx)
2026 · Larry Anderson, Lin Wang, et al. · Clinical Lymphoma Myeloma & Leukemia
Journey of Relapsed or Refractory Multiple Myeloma (RRMM) after Quadruple-Class Exposure (QCEx): Poor Outcomes and High Attrition
2026 · Doris K. Hansen, Lin Wang, et al. · Transplantation and Cellular Therapy
Trial in Progress: QUINTESSENTIAL—a Phase 2 study of Arlocabtagene Autoleucel (arlo-cel) in Patients with relapsed/refractory Multiple Myeloma (RRMM)
2026 · Ciara L Freeman, Nisha Joseph, et al. · Transplantation and Cellular Therapy
Supplementary Data Figures from A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
2025 · Michael J. Dickinson, Pere Barba, et al.
Supplementary Data Tables from A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
2025 · Michael J. Dickinson, Pere Barba, et al.
PDF
Journey of relapsed or refractory multiple myeloma (RRMM) after quadruple-class exposure (QCEx): Poor outcomes and high attrition
2025 · Doris Hansen, Lin Wang, et al. · Blood
PDF
Treatment Patterns and Outcomes in Quad-Class Exposed (QCE) Relapsed Refractory Multiple Myeloma (RRMM): Investigating Critical Unmet Needs
2025 · Doris Hansen, Lin Wang, et al. · Clinical Lymphoma Myeloma & Leukemia
Trial in Progress: QUINTESSENTIAL—A Phase 2 Study of Arlocabtagene Autoleucel (arlo-cel) in Triple- and Quad-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma (RRMM)
2025 · Krina Patel, Sarah Larson, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 47
Citation count: 260
H-index: 6
I10-index: 6
Year
Topic
Type